ORLANDO, Florida — Roche announced recently new Phase II efficacy data from the investigational compound GA101 (RG 1759) in relapsed/refractory non-Hodgkin’s lymphoma (NHL), a common type of blood cancer.
ORLANDO, Florida — Roche announced recently new Phase II efficacy data from the investigational compound GA101 (RG 1759) in relapsed/refractory non-Hodgkin’s lymphoma (NHL), a common type of blood cancer.
Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!